
SGYP
Other · Other
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2018
EPS trend, 90 days to now · +7.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 8, 2018 | Time not confirmed | -0.14 | -0.14 | 0.0% |
| May 10, 2018 | Time not confirmed | -0.16 | -0.15 | +6.3% |
| Feb 1, 2018 | Time not confirmed | -0.19 | -0.16 | +15.8% |
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops…